Business
PDS Q3 Results and Business Update
PDS Q3 Results and Business Update.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n For immediate release: RNS Reach\n \n \n \n \n NetScientific plc\n \n \n \n (\"NetScientific\" or the \"Company\")\n \n \n \n PDS Biotech Third Quarter 2022 Financial Results and Business Update\n \n \n \n NetScientific Plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, reports that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced its financial results for the quarter ended 30 September 2022.\n \n \n \n Highlights\n \n \n \n ·\n PDS0101 Lead Drug Candidate\n \n \n o \n VERSATILE-002 Phase 2 Clinical Trial\n \n \n §\n Hosted a key opinion leader roundtable discussion on current treatment of head and neck cancer, and how PDS0101 might fit into the treatment paradigm.\n \n \n §\n Announced a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), allowing progression to a registrational trial for VERSATILE-002.\n \n \n ·\n IMMUNOCERV Phase 2 Clinical Trial\n \n \n o \n Presented preliminary data on the clinical efficacy and safety of the combination of PDS0101 and chemoradiotherapy, as well as immunological correlates in the IMMUNOCERV Phase 2 trial being conducted at The University of Texas MD Anderson Cancer Center in locally, advanced cervical cancer at the Society for Immunotherapy of Cancer Conference (SITC) 2022.\n \n \n ·\n NCI-led Triple Combination Phase 2 Clinical Trial\n \n \n o \n Presented data on immunological correlates associated with clinical benefit in patients with HPV-positive checkpoint inhibitor (CPI) refractory cancer treated with the PDS0101-based triple combination in the National Cancer Institute (NCI)-led Phase 2 clinical trial at the Society for Immunotherapy of Cancer Conference (SITC) 2022.\n \n \n o \n Reported expanded interim data for the Phase 2 PDS0101 based triple combination trial led by the NCI targeting advanced HPV-positive cancers.\n \n \n o \n Announced completion of recruitment into the NCI-led PDS0101-based triple combination Phase 2 trial, and also reported selection of the CPI refractory arm as the preferred patient group to target in a registrational study with the triple combination.\n \n \n ·\n PDS0102 and PDS0103 Drug Candidates\n \n \n o \n Presented preclinical data on both PDS0102 and PDS0103, demonstrating the...